Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 819 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Candel Therapeutics, Inc.
Market Cap
$728.31M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$725.80M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$733.15M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$712.22M
Gross Margin
53.23%
TTM Avg
53.64%
3Y Avg
56.38%
5Y Avg
57.18%
Market Cap
$710.62M
Gross Margin
60.02%
TTM Avg
59.55%
3Y Avg
55.45%
5Y Avg
55.70%
Market Cap
$746.36M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$701.23M
Gross Margin
100.00%
TTM Avg
141.50%
3Y Avg
99.31%
5Y Avg
94.19%
Market Cap
$695.29M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$761.20M
Gross Margin
40.44%
TTM Avg
20.22%
3Y Avg
20.22%
5Y Avg
20.22%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $728.31M | 0.00% | 0.00% | 0.00% | 0.00% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $725.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| Faeth Therapeutics, Inc. (FTH)vs › | $733.15M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cytek Biosciences, Inc. (CTKB)vs › | $712.22M | 53.23% | 53.64% | 56.38% | 57.18% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $710.62M | 60.02% | 59.55% | 55.45% | 55.70% |
| Design Therapeutics, Inc. (DSGN)vs › | $746.36M | 0.00% | 0.00% | 0.00% | 0.00% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $701.23M | 100.00% | 141.50% | 99.31% | 94.19% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $695.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $761.20M | 40.44% | 20.22% | 20.22% | 20.22% |
| Anteris Technologies Global Corp. (AVR)vs › | $694.30M | -16.57% | 15.14% | 17.91% | 27.64% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -790.32% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | -474.19% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | -10519.35% |
| 2021-03-31 | -8780.65% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | -5690.32% |
| 2020-03-31 | -5129.03% |
